{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:03:16Z","timestamp":1768572196045,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo","award":["#2017\/13109-1"],"award-info":[{"award-number":["#2017\/13109-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00296-019-04254-3","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T15:02:27Z","timestamp":1550502147000},"page":"1201-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intravenous human immunoglobulin and\/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-7663","authenticated-orcid":false,"given":"Jean Marcos","family":"de Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-4796","authenticated-orcid":false,"given":"Leonardo Santos","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3682-4517","authenticated-orcid":false,"given":"Samuel Katsuyuki","family":"Shinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"4254_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372:1734\u20131747","journal-title":"N Engl J Med"},{"key":"4254_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2990.2010.01153.x","volume":"37","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC (2011) Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 37:226\u2013242","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4254_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","volume":"17","author":"P Basharat","year":"2015","unstructured":"Basharat P, Christopher-Stine L (2015) Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep 17:72","journal-title":"Curr Rheumatol Rep"},{"key":"4254_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","volume":"250","author":"IM Bronner","year":"2003","unstructured":"Bronner IM, Hoogendijk JE, Wintzen AR, van der Meulen MF, Linssen WH, Wokke JH, de Visser M (2003) Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 250:480\u2013485","journal-title":"J Neurol"},{"key":"4254_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/RHU.0000000000000427","volume":"22","author":"MB Carroll","year":"2016","unstructured":"Carroll MB, Newkirk MR, Sumner NS (2016) Necrotizing autoimmune myopathy: a unique subset of idiopathic inflammatory myopathy. J Clin Rheumatol 22:376\u2013380","journal-title":"J Clin Rheumatol"},{"key":"4254_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, Gaudet (2012) Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 64:269\u2013272","journal-title":"Arthritis Care Res"},{"key":"4254_CR7","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen AL, Tiniakou E (2015) Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med 373:1680\u20131682","journal-title":"N Engl J Med"},{"key":"4254_CR8","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1136\/ard.2006.052191","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635\u20131638","journal-title":"Ann Rheum Dis"},{"key":"4254_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV (2004) Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50:209\u2013215","journal-title":"Arthritis Rheum"},{"key":"4254_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41:185\u2013190","journal-title":"Muscle Nerve"},{"key":"4254_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","volume":"76","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, Paik JJ, Ahlawat S, Danoff SK, Lloyd TE, Mammen AL, Christopher-Stine L (2017) Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 76:681\u2013687","journal-title":"Ann Rheum Dis"},{"key":"4254_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/keu422","volume":"54","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Liu L, Wang L, Xiao J, Wang Z, Lv H, Zhang W, Yuan Y (2015) Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle. Rheumatology 54:1017\u20131024","journal-title":"Rheumatology"},{"key":"4254_CR13","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62:2757\u20132766","journal-title":"Arthritis Rheum"},{"key":"4254_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/acr.20662","volume":"64","author":"AL Mammen","year":"2012","unstructured":"Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, Gaudet D (2012) Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 64:269\u2013272","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4254_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","volume":"73","author":"T Miller","year":"2002","unstructured":"Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:420\u2013428","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4254_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, Hayashi YK, Suzuki N, Nishino I (2015) Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 10:61","journal-title":"Orphanet J Rare Dis"},{"key":"4254_CR17","first-page":"766","volume":"35","author":"FHC Souza De","year":"2017","unstructured":"De Souza FHC, Miossi R, Shinjo SK (2017) Necrotising myopathy associated with anti-signal recognition particle (anti-SRP) antibody. Clin Exp Rheumatol 35:766\u2013771","journal-title":"Clin Exp Rheumatol"},{"key":"4254_CR18","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964","journal-title":"Ann Rheum Dis"},{"key":"4254_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"MG Cruellas","year":"2013","unstructured":"Cruellas MG, Viana VS, Levy-Neto M, Souza FHC, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68:909\u2013914","journal-title":"Clinics"},{"key":"4254_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20035","volume":"62","author":"LG Rider","year":"2010","unstructured":"Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 62:465\u2013472","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4254_CR21","first-page":"167","volume":"30","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167\u2013178","journal-title":"J Rheumatol"},{"key":"4254_CR22","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9:789\u2013793","journal-title":"J Rheumatol"},{"key":"4254_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","volume":"43","author":"DA Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS) (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 43:49\u201354","journal-title":"Rheumatology"},{"key":"4254_CR24","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/art.21291","volume":"52","author":"CV Oddis","year":"2005","unstructured":"Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, International Myositis Assessment and Clinical Studies Group (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52:2607\u20132615","journal-title":"Arthritis Rheum"},{"key":"4254_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76:792\u2013801","journal-title":"Ann Rheum Dis"},{"key":"4254_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","volume":"23","author":"A Pestronk","year":"2011","unstructured":"Pestronk A (2011) Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 23:595\u2013604","journal-title":"Curr Opin Rheumatol"},{"key":"4254_CR27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","volume":"181","author":"C Preu\u03b2e","year":"2012","unstructured":"Preu\u03b2e C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, Koch A, Heppner FL, Stenzel W (2012) Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 181:2161\u20132171","journal-title":"Am J Pathol"},{"key":"4254_CR28","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1172\/JCI114387","volume":"84","author":"M Basta","year":"1989","unstructured":"Basta M, Kirshbom P, Frank MM, Fries LF (1989) Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 84:1974\u20131981","journal-title":"J Clin Invest"},{"key":"4254_CR29","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, Mccrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"4254_CR30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4","volume":"68","author":"M Ballow","year":"1991","unstructured":"Ballow M (1991) Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 68:1430\u20131436","journal-title":"Cancer"},{"key":"4254_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJM199201093260206","volume":"326","author":"JM Dwyer","year":"1992","unstructured":"Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107\u2013116","journal-title":"N Engl J Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04254-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04254-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T01:57:43Z","timestamp":1606528663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04254-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["4254"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04254-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"5 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jean Marcos de Souza, Leonardo Santos Hoff and Samuel Katsuyuki Shinjo declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}